Issue 183

05.02.2021

Europe
USA
Latam & Caribbean
APAC
Africa & Middle East

HIGHLIGHTS 

JAZZ PHARMA TAKES CONTROL OF WORLD’S MOST POPULAR CANNABIS-BASED MEDICINE

 

This week, Jazz Pharmaceuticals announced its acquisition of GW Pharmaceuticals in a US$7.2 billion deal, subject to regulator and shareholder approval.

As a result, the company will also gain control of Epidiolex, the cannabis-based medicine used to treat severe types of epilepsy in children.

READ MORE

 


 

HIGHLIGHTS

 

US GEARS TOWARDS FEDERAL CANNABIS REFORM

MGC PHARMACEUTICALS TO BE FIRST CANNABIS COMPANY LISTED ON LSE

 

Europe

REPORT

THE NORTH AMERICAN CANNABIS REPORT: SECOND EDITION

 

 

As 2021 commences and the North American cannabis industry continues to show promising developments, Prohibition Partners launches; The North American Cannabis Report: Second Edition, which provides a deep-dive on the current state of the cannabis industry in the US and Canada.

READ MORE

USA

PROHIBITION PARTNERS WEBINAR SERIES

INDUSTRY LEADERS DISCUSS KEY TRENDS SET TO DEFINE NORTH AMERICA CANNABIS MARKET

 

 

Next week, Prohibition Partners is hosting an exclusive panel discussion featuring leading figures from the North American cannabis sector.

This online launch event takes a look forward with the recent changes in the North American cannabis industry; across potential federal reform, ground-breaking social equity programmes and future market growth.

 

REGISTER FOR FREE NOW

CANADA

LATAM & CARIBBEAN

APAC

AFRICA & MIDDLE EAST

Read the stories that shape the cannabis industry